The Business Research Company’s report on the Amusement Parks Global Market Report 2025 Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the primary drivers fueling the growth of the myelodysplastic syndrome (mds) drugs market in recent years?
Rising exposure to cancer treatments, such as chemotherapy and radiation, is expected to boost the growth of the myelodysplastic syndrome (MDS) drug market going forward. Chemotherapy refers to using medications to eradicate cancer cells and radiation refers to a cancer treatment that uses high radiation doses to kill cancer cells and reduce tumors. Chemotherapy medications and radiation therapy harm the bone marrow’s stem cells, which are in charge of making new blood cells; this damaging effect disturbs the natural balance of cell creation and results in the onset of MDS. Myelodysplastic syndrome (MDS) drugs offer several benefits in managing and treating MDS, a group of disorders characterized by abnormal production of blood cells in the bone marrow. For instance, according to ESTRO-HERO (Health Economics in Radiation Oncology) analysis by the European Society of Radiation Oncology (ESTRO), a Belgium-based organization, based on projected cancer distributions in 2025, there is an expected 16% increase in the number of radiotherapy treatment courses. Therefore, rising exposure to cancer treatments, such as chemotherapy and radiation, is driving the growth of the myelodysplastic syndrome (MDS) drugs market.
Myelodysplastic Syndrome (MDS) Drugs Market Driver: Rising Incidences Of Myeloid Leukemia Boosts Myelodysplastic Syndrome (MDS) Drug Treatment Market
The increasing incidences of myeloid leukemia are expected to propel the growth of the myelodysplastic syndrome (MDS) drug treatment market going forward. Myeloid leukemia is a type of cancer that originates in the bone marrow and affects the cells responsible for producing various kinds of blood cells. Myelodysplastic syndrome (MDS) drugs aim to improve bone marrow function by targeting the root cause of leukemia to reduce the risk of complications with low blood cell counts, reduce the need for chemotherapy and transplants, and improve the survival rates for people with myelodysplastic syndrome (MDS) drugs. For instance, in January 2023, according to the estimates of the American Cancer Society, a US-based voluntary health organization, there were about 20,380 cases and 11,310 deaths of acute myeloid leukemia (AML) will be in adults during 2023. Therefore, the increasing incidences of myeloid leukemia drive the myelodysplastic syndrome (MDS) drug market.
Access Your Free Sample of the Global Amusement Parks Global Market Report 2025 Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13043&type=smp
What is the projected market size of the myelodysplastic syndrome (mds) drugs industry, and how is it expected to grow?
The myelodysplastic syndrome (MDS) drugs market size has grown strongly in recent years. It will grow from $3.47 billion in 2024 to $3.73 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to aging population, advancements in targeted therapies, clinical trials, increased awareness.
The myelodysplastic syndrome (MDS) drugs market size is expected to see strong growth in the next few years. It will grow to $5.12 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to genomic research, immunotherapies, global expansion of healthcare, biomarker identification. Major trends in the forecast period include personalized medicine, combinatorial therapies, symptom management, data sharing and collaboration.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=13043&type=smp
Who are the key players driving competition in the myelodysplastic syndrome (mds) drugs market?
Major companies operating in the myelodysplastic syndrome (mds) drugs market are Bristol Myers Squibb, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma Inc., Aprea Therapeutics, Onconova Therapeutics Inc., Geron Corporation, Amgen Inc., Sandoz, Gilead Sciences Inc., Johnson And Johnson, Lupin Ltd. Corporation, Ono Pharmaceutical Co. Ltd., Eisai Co. Ltd., Nippon Shinyaku Co. Ltd., Lupin Ltd., Accord Healthcare Inc., Kite Pharma Inc., Karyopharm Therapeutics Inc., Aprea Therapeutics Inc., Acceleron Pharma Inc., Astex Pharmaceuticals Inc., Stemline Therapeutics Inc., Geron Corporation, Onconova Therapeutics Inc., Actinium Pharmaceuticals Inc., Millennium Pharmaceuticals Inc.
What key trends are expected to drive the myelodysplastic syndrome market during the forecast period?
Major companies operating in the myelodysplastic syndrome (MDS) drugs market focus on developing new products such as targeted therapy to improve patient outcomes, meet specific customer needs, and fit the ecosystem. Targeted therapy for myelodysplastic syndromes (MDS) involves using drugs that specifically target genetic mutations or molecular abnormalities in cancer cells, aiming to improve outcomes by selectively attacking abnormal cells while minimizing damage to healthy tissue. For instance, in October 2023, the U.S. Food and Drug Administration (FDA) approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation. The effectiveness of Tibsovo for this new indication was evaluated in an open-label, single-arm, multicenter study of 18 adult patients with relapsed or refractory MDS with an IDH1 mutation.
Which key geographies are driving the growth of the myelodysplastic syndrome (mds) drugs market?
North America was the largest region in the myelodysplastic syndrome (MDS) drugs market in 2024. The regions covered in myelodysplastic syndrome (MDS) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Order Your Report Now For Swift Delivery
What are the key segments driving growth in the myelodysplastic syndrome (mds) drugs market?
The myelodysplastic syndrome (MDS) drugs market covered in this report is segmented –
1) By Drug Type: Chemotherapy, Immunomodulatory Drugs
2) By Route Of Administration: Oral, Parenteral
3) By Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts
4) By End User: Hospitals, Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Chemotherapy: Hypomethylating Agents, Cytotoxic Agents
2) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13043
How is the myelodysplastic syndrome (mds) drugs market defined, and what are its core characteristics?
Myelodysplastic syndrome (MDS) drugs are medications used to treat myelodysplastic syndrome, a collection of several bone marrow illnesses in which the bone marrow fails to create enough healthy blood cells. They work by helping to restore normal gene function in bone marrow cells and produce more red blood cells.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
